Antithrombotic treatment in patients with atrial fibrillation
| CVA, cerebrovascular accident; HCM, hypertrophic cardiomyopathy; INR, international normalised ratio; LV, left ventricular; TIA, transient ischemic attack. | |
| Oral anticoagulation (optimal INR 2–3): | |
| ▸ Rheumatic heart disease (mitral stenosis) | |
| ▸ Prosthetic heart valve | |
| ▸ High risk patients: | |
| –history of CVA or TIA | |
| –hypertension | |
| –diabetes mellitus | |
| –heart failure | |
| –age >65 years | |
| –echocardiogram: LV dysfunction, HCM | |
| –thyrotoxicosis | |
| Aspirin (75–325 mg/daily): | |
| ▸ “Lone” atrial fibrillation | |
| ▸ No risk factors | |
| ▸ Age <65 years | |
| Contraindication for oral anticoagulation | |